Moderna, the creators of one of the COVID-19 vaccines, announced that it will work to develop three new mRNA vaccine candidates in 2021 for HIV, seasonal flu, and the Nipah virus.
It has been speculated that mRNA vaccine candidates could have high potential due to the added flexibility of mRNA technology. The technology is different from previous vaccines because it triggers the human body to create proteins that can trigger a defence response from the body. The new mRNA vaccines also do not rely on using parts of an active or dormant virus similar to previous vaccines.
Moderna’s HIV vaccine candidate is being developed in collaboration with the AIDS Vaccine Initiative and also the Bill and Melinda Gates Foundation, and it is scheduled to enter Phase 1 trial before the end of the year.
Image Credit: Shutterstock